title: Effectiveness of montelukast in pediatric patients with allergic rhinitis.
abstract: Allergic rhinitis (AR) is one of the most common chronic diseases of childhood and carries significant morbidity as well as physical and psychosocial consequences. Therapy aims to alleviate clinical symptoms, prevent complications and improve psychosocial consequences. Leukotrienes which are amongst the main mediators in pathogenesis of AR have chemotactic properties and lead to increased vascular permeability. Thus, leukotriene antagonism may be an effective therapeutic option in treatment of allergic diseases, specifically AR. Montelukast which is a leukotriene receptor type I inhibitor has variable efficacy in children with AR and the guidelines recommend its use in children with seasonal AR aged six years and above. Although its efficacy is inferior to anti-histamines and intranasal corticosteroids, combination treatment may warrant clinical efficacy. Therefore, montelukast may be considered to be a well-tolerated therapeutic option for children with AR with minor side effects though long term results need to be assessed. In conclusion, larger scale research enrolling pediatric cases with seasonal and persistent AR are required before concise recommendations about montelukast use in pediatric AR can be made.
authors.affiliation: Celal Bayar University Medical Faculty, Department of Pediatric Allergy and Pulmonology, Manisa, Turkey. Electronic address: oyilmaz_76@hotmail.com.
authors.forename: Ozge
authors.initials: O
authors.lastname: Yilmaz
authors.forename: Derya
authors.initials: D
authors.lastname: Altintas
authors.forename: Carmen
authors.initials: C
authors.lastname: Rondon
authors.forename: Cemal
authors.initials: C
authors.lastname: Cingi
authors.forename: Fatih
authors.initials: F
authors.lastname: Oghan
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010372:Pediatrics; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast
keywords: Allergic rhinitis; Children; Leukotriene receptor antagonist; Montelukast